<DOC>
	<DOCNO>NCT00836706</DOCNO>
	<brief_summary>This study compare relative bioavailability ( rate extent absorption ) 500 mg Clarithromycin Tablets 500 mg BIAXINÂ® Tablets follow single oral dose ( 1 x 500 mg tablet ) healthy adult subject non-fasting condition .</brief_summary>
	<brief_title>Clarithromycin 500 mg Tablets Under Non-Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>All subject select study healthy men woman 18 year age old time dose . The subject 's body mass index ( BMI ) less equal 30 . Each subject complete screening process within 28 day prior period I dose . Consent document screen evaluation HIV antibody determination review , discuss sign potential participant full implementation screening procedure . Screening include general observation , physical examination , demographic , medical medication history , electrocardiogram , sit blood pressure heart rate , respiratory rate temperature . The physical examination include , may limit , evaluation cardiovascular , gastrointestinal , respiratory central nervous system . The screen clinical laboratory procedure include : HEMATOLOGY : hematocrit , hemoglobin , WBC count differential , RBC count , platelet count CLINICAL CHEMISTRY : serum creatinine , BUN , glucose , AST ( GOT ) , ALT ( GPT ) , albumin , total bilirubin , total protein , alkaline phosphatase HIV antibody , hepatitis B surface antigen , hepatitis C antibody screen URINALYSIS : dipstick ; full microscopic examination dipstick positive URINE DRUG SCREEN : ethyl alcohol , amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine metabolite , opiates phencyclidine SERUM PREGNANCY SCREEN ( female subject ) FOLLICLE STIMULATING HORMONE ( FSH ; female subject ) : verify postmenopausal status If female : postmenopausal least 1 year ; surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) . Subjects recent history drug alcohol addiction abuse . Subjects presence clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease ( determined clinical investigator ) . Subjects whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant . Subjects demonstration positive hepatitis B surface antigen screen , hepatitis C antibody screen reactive HIV antibody screen . Subjects demonstrate positive drug abuse screen screen study . Female subject currently breast feeding . Female subject demonstrate positive pregnancy screen . Subjects history allergic response ( ) Clarithromycin relate drug . Subjects history clinically significant allergy include drug allergy . Subjects clinically significant illness 4 week prior Period I dose ( determined clinical investigator ) . Subjects currently use report use tobacco nicotinecontaining product within 90 day prior Period I dose . Subjects take drug know induce inhibit hepatic drug metabolism 30 day prior Period I dose . Subjects report donate great 150 mL blood within 30 day prior Period I dose . All subject advise donate blood four week complete study . Subjects donate plasma ( e.g . plasmapheresis ) within 14 day prior Period I dose . All subject advise donate plasma four week complete study . Subjects report receive investigational drug within 30 day prior Period I dose . Subjects report take prescription medication 14 day prior Period I dose , exception topical product without systemic absorption . Subjects abnormal diet 28 day prior Period I dose . Subjects report intolerance direct venipuncture .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>